brexucabtagene autoleucel (Tecartus, Zynteglo)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

* 20,000,000 CELLS/ML Injection

Adverse effects

* Warnings

Mechanism of action

More general terms

References

  1. FDA Cellular and Gene Therapy Products. Aug 14, 2020 TECARTUS (brexucabtagene autoleucel) https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel
  2. FDA July 27, 2020 FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
  3. WikipediaL Brexucabtagene autoleucel https://en.wikipedia.org/wiki/Brexucabtagene_autoleucel